Nature Reviews Drug Discovery
@NatRevDrugDisc
Editorial team of Nature Reviews Drug Discovery.
Advances in the treatment of systemic lupus erythematosus nature.com/articles/s4157… This new Review covers approaches aimed at specific immune pathways and efforts to restore immune homeostasis, such as CAR T cell therapies to eliminate B cells and regulatory T cell therapies
The rise of China’s pharmaceutical industry from 2015–2024 nature.com/articles/d4157… This new article analyses the growth in drug innovation in China, the underlying environmental factors and strategic trends such as the outlicensing of assets originating in Chinese companies

The non-small-cell lung cancer drug market nature.com/articles/d4157… This new article by Rachel Webster and Charlotte Jago @Clarivate analyses the pipeline and the market for NSCLC drugs, which is forecasted to nearly double by 2033

This new RNA therapeutics review is amazing. Easy to read, but not lacking depth.
RNA chemistry and therapeutics nature.com/articles/s4157… This new Review covers synthetic methods applied to RNA therapeutics in multiple classes and chemical modification strategies being used to enhance their properties @yizhoudonglab @WeissmanLab
For readers interested in N-of-1 therapies, this recent article from authors @irdirc discusses progress and a roadmap for their development nature.com/articles/s4157… rdcu.be/ewDqP

Building on the momentum of N-of-1 base editor therapies for rare diseases nature.com/articles/d4157… Rebecca Ahrens-Nicklas at the Children’s Hospital of Philadelphia discusses her groundbreaking application of a gene-editing therapy for an ultra-rare urea cycle disorder

FDA new drug approvals in Q2 2025 nature.com/articles/d4157… Just one of the nine new drugs approved by the FDA in Q2 is forecasted to be a blockbuster. Find out more in this article by Paul Verdin @evaluatepharma

CRISPR-based therapeutic genome editing for inherited blood disorders nature.com/articles/s4157… This new Review discusses the application of genome editing technologies including nucleases, base editors and prime editors to treat patients with inherited haematological disorders

RNA chemistry and therapeutics nature.com/articles/s4157… This new Review covers synthetic methods applied to RNA therapeutics in multiple classes and chemical modification strategies being used to enhance their properties @yizhoudonglab @WeissmanLab

FDA approves first factor XIIa inhibitor, for hereditary angioedema nature.com/articles/d4157… CSL's first-in-class monoclonal antibody therapy garadacimab provides a once-monthly preventative option


If you enjoyed our RNA splicing collection, this @NatRevDrugDisc Review may be of interest: Protein isoform-centric therapeutics: expanding targets and increasing specificity go.nature.com/4lVcwy9
Our June issue is live and includes an editorial on RNA splicing (go.nature.com/436CKXZ) that acts as a foreword for a new joint collection by @NatureRevGenet and @NatRevMCB on this topic: go.nature.com/3FjZx9F
FDA approves twice-yearly capsid inhibitor for HIV prevention nature.com/articles/d4157…

Unmet needs in vaccine development nature.com/articles/d4157… This new article examines the gap between infectious disease burden and vaccine availability, underscoring the role of vaccine innovation and proposing actions to advance equitable vaccine research and development

The US biosimilars market after one decade nature.com/articles/d4157… This new article analyses policies and strategies affecting biosimilar adoption in the US, and considers the outlook for the development of the biosimilar market in the next five years

A first-in-class drug for the inflammatory lung disease bronchiectasis that could be approved by the FDA in the next few weeks is anticipated to have peak sales of more than $4 billion. Find out more in this news story in the July issue nature.com/articles/d4157…

Dual-payload antibody-drug conjugates move into first oncology clinical trials nature.com/articles/d4157… A rapidly growing cohort of companies are exploring if two different warheads may be better than one on ADCs, potentially unlocking durable anticancer efficacy

The changing landscape of medicinal chemistry optimization nature.com/articles/s4157… This new article analyses oral drug candidates and their corresponding hit and lead compounds from recent years and from the early 2000s, and discusses the implications of the observed trends

Pleased to share our review in @NatRevDrugDisc. 20+ years after the Hippo pathway was discovered in Drosophila, the first targeted therapies are in clinical trials for cancer and heart disease. 🙏 to co-author Tracy Tang from Vivace Tx. #TEADinhibitors rdcu.be/et2NL
Our July issue is live! Read about neutrophil-targeting drugs, tumour-agnostic kinase inhibitors, computational drug repurposing, antifibrotic therapies and more here nature.com/nrd/volumes/24…

For readers interested in novel therapeutic targets to combat Gram-negative bacterial infections, here's a comprehensive review nature.com/articles/s4157… rdcu.be/euuNs
